353 related articles for article (PubMed ID: 32781527)
1. Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine.
Malenica I; Donadon M; Lleo A
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32781527
[TBL] [Abstract][Full Text] [Related]
2. Current options and future directions of systemic therapy for advanced biliary tract cancer.
Prete MG; Cammarota A; D'Alessio A; Zanuso V; Rimassa L
Explor Target Antitumor Ther; 2021; 2(5):416-433. PubMed ID: 36045701
[TBL] [Abstract][Full Text] [Related]
3. The epidemiological trends of biliary tract cancers in the United States of America.
Jiang Y; Jiang L; Li F; Li Q; Yuan S; Huang S; Fu Y; Yan X; Chen J; Li H; Li S; Liu J
BMC Gastroenterol; 2022 Dec; 22(1):546. PubMed ID: 36581813
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies.
Lo JH; Agarwal R; Goff LW; Heumann TR
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444422
[TBL] [Abstract][Full Text] [Related]
5. Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer.
Canale M; Monti M; Rapposelli IG; Ulivi P; Sullo FG; Bartolini G; Tiberi E; Frassineti GL
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830826
[TBL] [Abstract][Full Text] [Related]
6. Statins associate with lower risk of biliary tract cancers: A systematic review and meta-analysis.
Cheung KS; Yeung YWM; Wong WS; Li B; Seto WK; Leung WK
Cancer Med; 2023 Jan; 12(1):557-568. PubMed ID: 35698295
[TBL] [Abstract][Full Text] [Related]
7. Cell of origin in biliary tract cancers and clinical implications.
Moeini A; Haber PK; Sia D
JHEP Rep; 2021 Apr; 3(2):100226. PubMed ID: 33665585
[TBL] [Abstract][Full Text] [Related]
8. Menopausal hormone therapy and risk of biliary tract cancers.
Jackson SS; Pfeiffer RM; Gabbi C; Anderson L; Gadalla SM; Koshiol J
Hepatology; 2022 Feb; 75(2):309-321. PubMed ID: 34766362
[TBL] [Abstract][Full Text] [Related]
9. Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions.
Sturm N; Schuhbaur JS; Hüttner F; Perkhofer L; Ettrich TJ
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428670
[TBL] [Abstract][Full Text] [Related]
10. Current biologics for treatment of biliary tract cancers.
Zhao DY; Lim KH
J Gastrointest Oncol; 2017 Jun; 8(3):430-440. PubMed ID: 28736630
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab: an investigational agent for the treatment of biliary tract cancer.
Di Federico A; Rizzo A; Ricci AD; Frega G; Palloni A; Tavolari S; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):325-332. PubMed ID: 33307866
[No Abstract] [Full Text] [Related]
12. Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer.
Wang Y; Chen T; Li K; Mu W; Liu Z; Shi A; Liu J; Zhao W; Lian S; Huang S; Pan C; Zhang Z
Front Oncol; 2021; 11():777617. PubMed ID: 34778094
[TBL] [Abstract][Full Text] [Related]
13. [Biliary tract cancers : Molecular characterization and identification of novel prognostic markers].
Goeppert B
Pathologe; 2017 Nov; 38(Suppl 2):192-197. PubMed ID: 29063951
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for the treatment of biliary tract cancer: an evolving landscape.
Wilbur HC; Azad NS
Ther Adv Med Oncol; 2024; 16():17588359241235799. PubMed ID: 38449562
[TBL] [Abstract][Full Text] [Related]
15. Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures.
Rizzo A; Tavolari S; Ricci AD; Frega G; Palloni A; Relli V; Salati M; Fenocchio E; Massa A; Aglietta M; Brandi G
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33158162
[TBL] [Abstract][Full Text] [Related]
16. The choice for the optimal therapy in advanced biliary tract cancers: Chemotherapy, targeted therapies or immunotherapy.
Palmieri LJ; Lavolé J; Dermine S; Brezault C; Dhooge M; Barré A; Chaussade S; Coriat R
Pharmacol Ther; 2020 Jun; 210():107517. PubMed ID: 32109491
[TBL] [Abstract][Full Text] [Related]
17. Cholangiocarcinoma across England: Temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivation.
Tataru D; Khan SA; Hill R; Morement H; Wong K; Paley L; Toledano MB
JHEP Rep; 2024 Mar; 6(3):100983. PubMed ID: 38357420
[TBL] [Abstract][Full Text] [Related]
18. Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review.
Yoo C; Shin SH; Park JO; Kim KP; Jeong JH; Ryoo BY; Lee W; Song KB; Hwang DW; Park JH; Lee JH
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916008
[TBL] [Abstract][Full Text] [Related]
19. Evolving Paradigms in the Systemic Treatment of Advanced Gallbladder Cancer: Updates in Year 2022.
Hu ZI; Lim KH
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267556
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer: Adding New Flavors to the Pizza.
Queiroz MM; Lima NF; Biachi de Castria T
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
